Pharmacy Medical News about Mucormycosis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Antimicrobial Agents and Chemotherapy, 06/29/09

Spellberg B et al. - Deferasirox was administered for an average of 14 days at 5 to 20 mg/kg of body weight/day. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

<< Previous
Hepatitis from Greater celandine (Chelidonium majus L.): Review...

Next >>
In vitro anti-HIV activity of five selected South African...

A Successful Combined Endovascular and Surgical Treatment of A Cranial Base Mucormycosis With An Associated Internal Carotid Artery Pseudoaneurysm
Neurosurgery, 10/07/09 Relevance Score: 88%

Rhino-Orbital-Cerebral Mucormycosis: A Lethal Complication of Body Dysmorphic Disorder
Ophthalmic Plastic and Reconstructive Surgery, 10/06/09 Relevance Score: 83%

Ulcerative leg nodules in a transplant recipient
Cleveland Clinic Journal of Medicine, 10/16/09 Relevance Score: 82%